Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy by Daniel Landi et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 26 November 2014
doi: 10.3389/fonc.2014.00338
Human cytomegalovirus antigens in malignant gliomas
as targets for adoptive cellular therapy
Daniel Landi 1,2*, Meenakshi Hegde1,2 and Nabil Ahmed 1,2,3*
1 Center for Cell and GeneTherapy, Baylor College of Medicine, Houston, TX, USA
2 Hematology and Oncology, Texas Children’s Cancer Center, Houston, TX, USA
3 Houston Methodist Hospital, Houston, TX, USA
Edited by:
Charles Stringfellow Cobbs, Swedish
Neuroscience Institute, USA
Reviewed by:
Rajiv Khanna, QIMR Berghofer
Medical Research Institute, Australia
Frank Kruyt, University Medical
Center Groningen, Netherlands
*Correspondence:
Daniel Landi and Nabil Ahmed,
Center for Cell and GeneTherapy,
Baylor College of Medicine, 1102
Bates Street, MC 3-3320, Houston,
TX 77030, USA
e-mail: landi@bcm.edu,
nahmed@bcm.edu
Malignant gliomas are the most common primary brain tumor in adults, with over 12,000
new cases diagnosed in the United States each year. Over the last decade, investiga-
tors have reliably identified human cytomegalovirus (HCMV) proteins, nucleic acids, and
virions in most high-grade gliomas, including glioblastoma (GBM). This discovery is sig-
nificant because HCMV gene products can be targeted by immune-based therapies. In
this review, we describe the current level of understanding regarding the presence and
role in pathogenesis of HCMV in GBM. We describe our success detecting and expanding
HCMV-specific cytotoxic T lymphocytes to kill GBM cells and explain how these cells can
be used as a platform for enhanced cellular therapies. We discuss alternative approaches
that capitalize on HCMV infection to treat patients with HCMV-positive tumors. Adoptive
cellular therapy for HCMV-positive GBM has been tried in a small number of patients with
some benefit, but we reason why, to date, these approaches generally fail to generate
long-term remission or cure. We conjecture how cellular therapy for GBM can be improved
and describe the barriers that must be overcome to cure these patients.
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BACKGROUND
Malignant gliomas are the most common primary brain tumor
in adults, with over 12,000 new cases diagnosed in the United
States each year (1). Glioblatoma (GBM) is the most common
and lethal of the gliomas, and debilitating cognitive and motor
deficits in patients who undergo surgical resection or radiation
are common. Currently, the standard of care utilizing surgery,
radiation, and the alkylating agent, temozolomide, leave GBM
patients with a dismal median survival time of 15 months after
diagnosis (1).
Although adoptive cellular therapies, particularly those using
cytotoxic T cells (CTL), have been effective in treating dissemi-
nated viral infections (2) and Epstein-Barr Virus-associated malig-
nancies (3, 4), successes in treating patients with solid tumors
by targeting tumor-associated antigens (TAA) have been more
tempered. A subversive and strongly suppressive tumor microen-
vironment coupled with a paucity of adequately presented tumor
antigens has limited the in vivo impact in early efforts.
Over the last decade, investigators have reliably identified
human cytomegalovirus (HCMV) proteins, nucleic acids, and
virions in most high-grade gliomas. This discovery is significant
because HCMV gene products can be targeted by immune-based
therapies, offering a new therapeutic approach for patients with
HCMV-positive GBM.
Human cytomegalovirus is a β-herpes virus tropic for human
glial cells, and between 50 and 90% of the world’s population
is infected (5, 6). In most people, the virus remains latent after
a primary infection, quelled by an effective adaptive immune
response. Virus-infected cells are the natural target of cytotoxic
T lymphocytes, and while debate continues regarding the role
HCMV might have in tumorigenesis or tumor progression in
GBM, HCMV-encoded proteins are certainly among the most
appealing TAA identified for GBM so far.
In this review, we describe the current level of understand-
ing regarding the presence and role in pathogenesis of HCMV in
GBM. We describe our success in detecting and expanding HCMV-
specific CTLs to kill GBM cells. We discuss other important
immune-based techniques for killing GBM and describe alterna-
tive approaches that capitalize on HCMV infection in a subset of
GBM patients. Adoptive cellular therapy for HCMV-positive GBM
has been tried in a handful of patients with some benefit, but we
reason why, to date, these approaches generally fail to generate
long-term remission or cure. We conjecture how cellular therapy
for GBM can be improved and describe the barriers that must be
overcome to cure these patients.
HCMV ELEMENTS IN GLIOBLASTOMA
Human cytomegalovirus DNA and proteins have been found
in 90–100% of primary GBM samples, as well as medulloblas-
toma, colon, prostate, and breast cancers (6–10). While initial
reports differed on the prevalence of HCMV early or late protein
expression in GBM (11), or whether HCMV could be identi-
fied at all (12), more recent reports utilizing standardized detec-
tion methods suggest that most high-grade gliomas, particularly
GBM, contain HCMV early and late proteins (7). The thickness
of paraffin block sections is important for optimizing detection
of HCMV proteins, and 6µm is an accepted standard for this
process (6).
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Under optimal conditions for detecting low levels of expression,
detection of HCMV proteins in adult GBM is usually reported in
80–100% of tumor samples (6, 8, 13–15). We found that a high
proportion of GBMs in children also contain intermediate-early 1
(IE1) and pp65, although the rate of HCMV-protein expression in
pediatric GBM was lower than reported values for adults (Corder,
Ahmed et al., in review).
Although HCMV expression is ubiquitous in GBMs, virus-
specific oligonucleotides are not observed in areas of necrosis or
in healthy tissue outside the tumor margin (6–8, 11, 15). Using
consensus methods to section and fix primary GBM samples (7),
we have shown complete concordance of pp65 and IE-1 detection
between immunohistochemistry and in situ hybridization tech-
niques (15). IE1 has been found in over 90% of GBM samples,
and immunoreactivity to IE1 is generally limited to the nuclei
and perinuclear cytoplasm of GBM tumor cells (11). We have
detected pp-65 primarily in a nuclear distribution in GBM cells,
but pp65 does not appear to be as prevalent as IE1 in terms
of detection within GBM samples and within individual tumor
cells (15). Cobbs and colleagues have also consistently generated
HCMV DNA and RNA in GBM samples (6).
Although astrocytic tumors appear to express HCMV most
often, oligodendrocytic tumors and, to a lesser extent, ependymal
tumors also express HCMV (8). Within GBM tumors, Sheurer
and colleagues (8) found that 79% of tumor cells were positive for
HCMV IE1 using an immunoreactive probe. Four percent of cells
in non-tumor areas of tissue in patients with GBM were positive
for IE1 using similar detection methods. While CMV nucleic acids
and, likely, virions have been detected in patient samples (6), CMV
gene expression in human and some animal models appears to be
transient, and viral DNA is often not found in clonal cell lines
derived from transformed foci (15, 16).
LIKELY ROLE OF HCMV IN HIGH-GRADE GLIOMA
PATHOGENESIS AND TUMOR PROGRESSION
Whether HCMV plays a role in the development of GBM from
astrocytes is unknown. The prevalence of HCMV gene expres-
sion products in patient GBM samples and the apparent interplay
between HCMV and GBM pathways suggest HCMV can pro-
mote tumor progression, if not help trigger GBM tumorigenesis.
Reactivation of similar herpesviruses such as EBV and human
herpesvirus-8 (HHV8) can lead to malignant transformation, and
important cellular pathways in glioma biology are promoted by
HCMV gene expression (6).
The CMV genome encodes roughly 200 proteins, many of
which are not necessary for replication (17). HCMV gene tran-
scription can be activated in myeloid cells (18) and astrocytic cells
(6) in the setting of inflammation. Within GBM, HCMV-proteins
appear to impact telomerase activity, cellular differentiation, apop-
tosis, and migration (19, 20). In particular, US28 is a HCMV-
encoded G-protein coupled receptor found primarily in vascular
endothelial cells of GBM tumors that generates immunomodula-
tory effects through increasing IL-6 production (21). US28 induces
COX-2 expression and results in signal transducer and activa-
tion of transcription 3 (STAT3) phosphorylation. STAT3 activity
increases production of vascular endothelial growth factor (VEGF)
and IL-6, ultimately promoting tumor formation in vivo (22).
Interestingly, HCMV is particularly tropic to both monocytes,
which give rise to central nervous system (CNS) macrophages
and microgila, and CD133+ glioma stem cells (GSCs) (5). GSCs
produce colony stimulating factor-1, transforming growth fac-
tor (TGF) β1, and macrophage inhibitory cytokine-1 – cytokines
known to recruit macrophages/microglia (23). HCMV-expressing
GSCs also produce HCMV IL-10, a viral homolog of human
IL-10 (24). HCMV IL-10 – treated monocytes produce angio-
genic VEGF and TGF-β (5). The overall effect is the induction of
the M2 phenotype characteristic in GBM-associated macrophages
and microglia. In this way, HCMV is implicated in promoting
an M2 immunosuppressive phenotype in monocyte-derived cells
in GBM.
The M2 phenotype is characterized by downregulation of
major histocompatibility (MHC) machinery and co-stimulatory
surface molecules, with simultaneous upregulation of immunoin-
hibitory molecules, specifically B7-H1 (25). In non-GBM patients,
transcriptome analysis has shown that HCMV-infected mono-
cytes display a unique M1/M2 polarization signature that was
skewed toward the classical M1 activation phenotype (26). How-
ever, HCMV-induced M2-associated genes are also expressed in
the presence of both NF-κB and phosphatidylinositol 3-kinase
(27). Whether HCMV might exert an overall immune-promoting
versus regulatory effect on the M1/M2 axis is unknown, but clearly
the ultimate result in GBM patients is a powerful regulatory M2
phenotype.
In addition to stimulating VEGF and TGF-β, HCMV IL-10
also induces expression of the HCMV-protein IE1, a modulator
of viral replication and transcription in monocytes (5). In mono-
cytes harboring HCMV, IE1 expression was induced after exposure
to HCMV IL-10, possibly potentiating a feed-forward mecha-
nism whereby HCMV could produce an M1/M2 polarization
signature that promotes viral dissemination and persistence (7).
GBM cell lines exposed to persistent IE-1 expression also exhib-
ited dysregulation of phosphatidylinositol 3-kinase/AKT activity,
retinoblastoma protein (Rb) phosphorylation, and expression of
the p53 family of proteins (28), but the precise onco-modulatory
mechanisms of IE-1 and other HCMV proteins are incompletely
understood.
Collectively, GBM cells are well-known to impair the
immune response through inhibitory cytokines, including IL-10,
prostaglandin-E2, and TGF-β (29). Inhibitory pathways involve
STAT3 activity, and inhibition of phagocytosis and increased IL-
10 secretion were reversed when the STAT3 pathway was blocked
in GSCs (23).
In most healthy individuals, HCMV remains latent through-
out the lifetime of the host. Bone marrow CD34+ progenitor
cells have been identified as one site of HCMV latency and the
latent viral genome is carried through the myeloid lineage as
these cells differentiate (18). While the latent state was previ-
ously regarded as a quiescent state with little transcription, HCMV
is now known to express numerous proteins in latent states as
well (18, 30).
While HCMV proteins and nucleic acids appear in most GBMs,
the precise nature of and effect of specific HCMV gene expres-
sion in these patients remain poorly understood. To date, active
viral replication in human gliomas has not been detected. Overall,
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current consensus opinion is that HCMV appears to play a
significant oncomodulatory role in GBM (7).
TARGETING CMV ANTIGENS IN MALIGNANT GLIOMAS
WITH ADOPTIVE CELLULAR THERAPY
Over the last 20 years, cellular therapies targeting GBM-associated
antigens have shown increasing promise. Active immunization
strategies have been predominant, and several groups have
reported improved survival and occasional long-term remissions
through these approaches (14). Interestingly, one reported patient
who received a dendritic cell vaccine generated from autologous
GBM tumor lysate had a robust CD8+ T-cell response to the
HCMV epitope pp65 after one injection of the vaccine (31).
Active immunization requires an immunogenic TAA, and a
sustained anti-tumor effect requires an element of continued stim-
ulation in vivo. An active immunization approach that targets a
ubiquitous viral epitope expressed in GBM cells could generate a
more sustained, robust in vivo anti-tumor response. In this way,
the presence of HCMV in GBM represents an important immuno-
genic target that can be used to improve cellular immunotherapy
for GBM and other CMV-positive tumors.
Adoptive cellular therapy can generate a large number of GBM-
specific effector cells, and these effector cells can be tested for
specificity and cytotoxicity ex vivo prior to infusion into a patient
with GBM. However, compared with active immunization, the
number of studies using adoptive cellular therapy to target GBM
is relatively small.
Our group generated polyclonal CMV-specific CTLs from
CMV-seropositive GBM patients for adoptive immunotherapy.
To evaluate whether IE1 and pp65 could be targeted by CMV-
specific T cells in GBM patients, we first measured the frequency
of pre-existing T cells targeting these antigens in a cohort of CMV-
seropositive GBM patients. All 11 patients in our cohort had T
cells specific for IE1 and pp65 assessed by IFN-γ enzyme-linked
immunospot assay (ELISA), although the precursor frequency of
pp65-specific CTLs was significantly lower than healthy donors.
Immunohistochemistry analyses of the primary GBM samples
from these 11 patients found IE1 in 10/11 (91%) and pp65 in
5/11 (45%) (15).
We successfully reactivated and expanded CMV-reactive clones
using antigen-presenting cells (APS) transduced with an adenovi-
ral vector encoding IE1 and pp65. Median T-cell expansion was
123-fold within 6 weeks of culture. We demonstrated the specific
cytotoxic effect of patient-derived, CMV-specific T cell products
against autologous GBM cells that were loaded with pp65 and IE1
using a standard chromium release assay (15).
Although we and others (15, 32, 33) have had excellent success
expanding and reactivating autologous HCMV-specific T cells in
CMV-seropositive patients, this is not possible for subjects who
are HCMV-seronegative. Interestingly, a significant proportion
of seronegative patients with GBM still have HCMV proteins in
their tumors. Debate continues whether these HCMV gene prod-
ucts are significant in GBM patients who lack serologic evidence
of HCMV infection based on conventional clinical assays (34).
Recent work demonstrating CMV-specific memory T and B cells
in seronegative patients indicates that traditional serology assays
are incomplete for determining whether a patient has been infected
with CMV (35).
In some instances, patients whose GBM contained higher lev-
els of HCMV products have decreased survival compared to
those with lower levels of HCMV expression, supporting the
role HCMV has in the pathogenesis and malignant phenotype
of GBM (13). Although a better understanding of the mecha-
nisms involved in HCMV onco-modulation is needed, HCMV
antigens can be targeted by host-derived T cells using adoptive cel-
lular transfer and represent an important target in immunotherapy
for GBM.
EXPANDING ADOPTIVE CELLULAR THERAPY USING
CMV-SPECIFICITY AS A PLATFORM
Targeting HCMV antigens displayed on MHC molecules through
the native, CMV-specific T-cell receptor (TCR) is a powerful
avenue for targeting HCMV-positive GBM using CTLs. Target-
ing CMV-positive GBM using polyclonal CMV-specific CTLs
affords a way to enhance survival, expansion, and cytotoxicity
of tumor-directed CTLs because of stimulatory signaling that
occurs with binding the native TCR. However, tumors frequently
escape immune targeting by downregulating MHC machinery or
co-stimulatory signaling molecules required for T-cell mediated
killing. Furthermore, targeting a single TAA is generally not clin-
ically effective because of numerous escape mechanisms and the
immunosuppressive tumor microenvironment, described below.
Using polyclonal CMV-specific CTLs as a platform, additional
targeting through adding chimeric antigen receptors (CAR) spe-
cific for a separate TAA is possible. CAR are artificial cell-surface
receptors composed of an epitope-binding extracellular domain
and an intracellular signaling domain. The extracellular domain
contains a single-chain variable fragment (scFv) incorporating
light and heavy variable chains of a monoclonal antibody joined
by a flexible linker. The scFV can be engineered to target larger
peptides, carbohydrates, or glycolipids in an HLA-independent
manner, unlike the TCR, which is restricted to smaller peptides
that have undergone cytoplasmic processing and display on MHC
machinery.
For optimal activation, all T cells require signaling through
binding both their TCRs as well as co-stimulatory molecules, pri-
marily CD28. Initial CAR T cells incorporating only the CD3-ζ
signaling remained dependent on binding co-stimulatory mole-
cules. Because most tumors do not express co-stimulatory factors,
the intracellular domain of the CAR can be enhanced by adding co-
stimulatory signaling domains, allowing a way of circumventing
downregluation of these molecules on tumor cells.
To date, a limited number of patients have received CMV-
specific adoptive cellular therapy as treatment for high-grade
glioma, summarized in Table 1. One patient with recurrent GBM
received adoptive transfer of expanded CMV-specific T cells and
temozolomide with no evidence of progression for 17 months
(33). Recently, CMV-specific T cells were successfully expanded
from 13 of 19 patients with recurrent GBM (68.4%). Eleven
patients received combination therapy consisting of T-cell infusion
and chemotherapy without significant toxicities related to T-cell
treatment. Whereas the historical median survival in patients with
recurrent GBM is less than 6 months, the median overall survival
in this group was 403 days, and four out of 10 patients that com-
pleted the treatment remained progression-free during the study
period (32).
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Table 1 | Patients receiving CMV-specific adoptive cellular therapy for recurrent or progressive GBM.
Investigator Intervention No. of patients Timeframe Outcomes
Ahmed
et al. (36)
Adoptive transfer of autologous
CMV-specific T cells genetically modified
with her-2 specific CAR
15 2010-present, not
recruiting
Pending
Crough
et al. (33)
Adoptive transfer of autologous
HCMV-specific T cells and temozolomide
1 Immunotherapy
in 2010
Improved response on MRI, stable clinically
after 17 months
Schuessler
et al. (32)
Adoptive transfer of autologous
HCMV-specific T cells
11 2009–2014 Median overall survival 403 days (range
133–2,428). Time to progression after infusion
was 108 to >1,783 days (median, 246). Four of
11 patients remained progression-free
Sampson
et al. (37)
Adoptive transfer of autologous
HCMV-specific T cells±pp65-LAMP
mRNA loaded dendritic cells
12 2008-present, not
recruiting
Pending
Building upon the platform of CMV-specific CTLs that have
been shown to kill CMV-positive GBM, we are studying the safety
and efficacy of autologous CMV-specific CTLs expressing a HER2-
specific CAR in patients with relapsed or refractory her2-positive,
CMV-positive GBM (36).
IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN
GBM
Our ability to exploit HCMV gene expression to target GBM is
limited by immunosuppressive characteristics of the tumor and
the tumor microenvironment. GBMs secrete inhibitory cytokines,
down-regulate antigen presentation and co-stimulatory molecule
expression, promote regulatory differentiation in macrophage and
APS lineages, and induce immune effector cells to undergo apop-
tosis. Below, we discuss immunosuppressive and tumor defense
mechanisms that must be overcome for CMV-directed therapies
or any immunotherapy approach, to be effective in GBM or other
solid tumors:
IMMUNOSUPPRESSIVE ROLE OF GLIOMA STEM CELLS
Within GBM tumors, a subpopulation of GSCs plays a prominent
role in creating the immune-suppressive tumor microenviron-
ment (38). These cancer-initiating cells are, by definition, mul-
tipotent and propagate the malignant characteristics of GBM and
have been shown to be preferentially infected by HCMV in vivo (5).
GSCs have been characterized by neurosphere formation in vitro
and expression of CD133, although no marker is completely sen-
sitive or specific for this population. Overall, GSCs tend to exhibit
immature antigens, including epidermal growth factor receptor
and nestin (39).
Glioma stem cells propagate tumor expansion by inhibiting
CTL proliferation and activation, triggering T-cell apoptosis, and
inducing FoxP3+ regulatory T cells (38). These effects are medi-
ated to a large extent by B7-H1 expression on the tumor cells, as
well as release of soluble factors including TGF-β and Galectin-3
(29). While expression of INF-γ is correlated with CTL killing
activity, INF-γ also induces upregulation of B7-H1 on tumor
cells, which binds to the suppressive cognate programed cell
death 1 (PD1) receptor on CTLs (1). Wei et al. (29) found the
suppressive effects of B7-H1 and Galectin-3 were diminished
on altering the differentiation of the GSCs, suggesting the most
potent suppressive mechanisms may come from GSCs. Galectin-
3 is produced by glioma cell lines but not normal astrocytes or
oligodendrocytes (40).
DIMINISHED ANTIGEN PRESENTATION IN THE CNS AND ANTIGEN
ESCAPE
The CNS does not appear to have a robust, immune generat-
ing population of APCs, and GBM cells are poor APCs (1). In
addition to the paucity of potent APCs in the CNS, MHC-class
1 is not generally expressed in normal CNS cells. Interestingly,
GBM cells do express MHC-class 1, and anti-GBM effect has been
shown through targeting MHC molecules by HLA-mismatched
CTLs (41). This approach is necessarily limited by an eventual
host immune response against the allogeneic, HLA-mismatched
effector cell. Even though GBMs appear to maintain some degree
of MHC expression and antigen-expression, the tumor mutes,
and subverts immune activation through inhibitory cytokines and
decreased expression of necessary co-stimulatory molecules such
as CD80 and CD86 (38).
In general, targeting multiple tumor antigens simultaneously
is more effective than targeting a single antigen. While target-
ing a single antigen may provide an initial response, this strategy
may ultimately select for antigen-negative tumor cells and lead to
tumor progression (42).
DOWNREGULATION OF CO-STIMULATORY MOLECULES AND
INHIBITORY SURFACE LIGANDS
Glioma stem cells isolated from human tumors express high lev-
els of MHC-class 1, but they express low levels of CD40, CD86,
and MHC-class 2 (29). Inadequate T-cell activation through lack
of co-stimulatory signals promotes T-cell anergy and can induce
apoptosis (43). In addition to hiding co-stimulatory signals needed
for effector cell activation, GBM also expresses inhibitory ligands,
particularly B7-H1 (44).
Co-culture experiments with GBM cells show decreased pro-
duction of IL-2 and interferon gamma (IFN-γ) by autologous
CD3+ cells (45), and these effects are mediated, in part, through
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binding the inhibitory co-stimulatory molecule B7-H1. Interest-
ingly, B7-H1 is upregulated by IFN-γ(2) and increases the propor-
tion of CD4+FoxP3+ Tregs in healthy donor PBMCs incubated
from supernatant from GBM cells, making CTL secretion of IFN-
γ a double-edged sword as part of the GBM-directed immune
response (38). Part of this inhibitory process is mediated by direct
contact of the effector cell with the B7-H1 molecule expressed on
GBM, as addition of a B7-H1 monoclonal antibody mitigates this
effect (29).
EFFECTOR CELL APOPTOSIS
In addition to increasing the proportion of regulatory CD4+ T
cells, GBM induces autologous T cells to undergo apoptosis. T cells
undergo apoptosis in co-culture experiments with GBM cells, as
well as in experiments where activated and non-activated T cells
are incubated with supernatant from GBM cells (29). Although
GBM has been reported to express the Fas ligand, the mechanisms
through which GBM induce immune cell apoptosis are varied and
can also involve B7-H1 signaling through both direct cell con-
tact and cytokine signaling. These pro-apoptotic signals involve
Galectin-3, which is produced to a greater extent by GSCs than
more differentiated GBM cells (29).
SUBVERSION OF MACROPHAGES/MICROGLIA AND DENDRITIC CELLS
TOWARD A REGULATORY PHENOTYPE
Histology from patient GBM samples frequently demonstrates sig-
nificant populations of infiltrative macrophages. However, most of
these infiltrative macrophages express the M2 phenotype, which
is characterized by expression of B7-H1 and overall regulatory,
immunosuppressive properties. This ability of the tumor microen-
vironment to both recruit monocytes/macrophages, and then steer
their development along the M2 axis is one of the most power-
ful evasion strategies protecting GBM from an effective immune
response (23, 46).
Although microglia may have some role as an antigen-
presenting cell in the CNS, dendritic cells are also prevalent in
resected GBM tumors. However, most dendritic cells in the CNS
are plasmacytoid dendritic cells, which exhibit a regulatory role
compared with myeloid dendritic cells (47). Through promot-
ing the M2 phenotype in monocyte differentiation and protecting
against the presence of professional APS, the GBM microenvi-
ronment can significantly impair activation and cytotoxicity of
effector cells (23).
IMMUNOSUPPRESSIVE CYTOKINES AND SIGNALING
Many of the above effects, including promoting an M2 phenotype
among CNS macrophages/microglia, stem from activation of the
STAT3 pathway. In GBM, STAT3 activation induces an immuno-
suppressive microenvironment by suppressing macrophage acti-
vation and decreasing expression of MHC-II, CD80, CD86, and
IL-12 in dendritic cells (Wei GBM cancer initiating). IL-6 and
epidermal growth factor upregulate STAT3 by phosphorylation.
Phosphorylated STAT3 (p-STAT3), which is overexpressed in most
gliomas translocates into the nucleus and induces a variety of
transcriptional factors, including IL-10. In turn, IL-10 adversely
influences Th1-mediated cytotoxic immune responses at multiple
levels and is essential for regulatory T-cell function.
Overall, this subversion of a Th1-directed response is a com-
mon effect of the immunosuppressive mechanisms of GBM and
other tumors. Interestingly, IL-21 appears to promote CD4+ T
cells along Th1 differentiation and may enhance their anti-tumor
effects. GBM cells were modified to secrete IL-21 prior to being
implanted into mice. These mice rejected subsequent GBM injec-
tions, and some mice with established GBM were salvaged by
receiving IL-21-expressing tumor cells (48).
ALTERNATE APPROACHES TO CELLULAR THERAPY
TARGETING HCMV IN GLIOMAS
The presence of HCMV in gliomas, including in GSCs, provides
antigenic targets for cellular therapy, but can also be used as
a mechanism for disrupting tumorigenesis by interfering with
important HCMV processes and pathways. The impact of valgan-
ciclovir in patients with GBM demonstrates how activity against
CMV can translate into clinical response against GBM (49).
In a study of 42 patients with GBM, the addition to val-
ganciclovir in a randomized, double-blind, placebo-controlled
trial showed significantly prolonged overall survival at 4 years
in patients who received at least 6 months of ganciclovir (50).
Valganciclovir has also been shown to slow HCMV-positive
medulloblastoma growth in murine models (51).
Similarly, cyclooxygenase-2 (COX-2) inhibition has shown effi-
cacy in slowing tumor pathogenesis in GBM. COX-2 upreglation
by the HCMV-protein US28 represents one way in which HCMV
contributes to GBM pathogenesis. These pathways involve VEGF
and STAT-3. COX-2-derived prostaglandins, particularly PGE2,
upregulate VEGF and STAT-3 production, ultimately promot-
ing tumor angiogenesis. Multiple studies, including large ret-
rospective analyses, suggest that regularly taking conventional
NSAIDs or aspirin significantly reduce the relative risk of death
from colon cancer and possibly glioma (52–54). In glioma biol-
ogy, the COX-2 pathway also induces expansion of a suppres-
sor population of myeloid cells in the glioma tumor microen-
vironment, where they limit CTL infiltration and anti-tumor
effect (53). An improved understanding of these pathways
and how they can be manipulated to shift the balance in
favor of anti-tumor effect could improve treatment options for
gliomas.
IMPROVING ADOPTIVE CELLULAR THERAPY FOR GBM
A growing number of glioma-associated antigens and our ability
to redirect CTLs to target these antigens – either through the native
TCR or a CAR – make adoptive cellular therapy a powerful tool
against gliomas. The presence of HCMV within a high proportion
of GBM creates an appealing platform for CTL-directed killing,
which can be expanded upon by targeting additional epitopes
through CARs, as described above.
While combinatorial targeting can prevent antigen escape, the
immunosuppressive tumor microenvironment limits the efficacy
of cellular therapies for HCMV-positive gliomas. To improve the
clinical effectiveness of immunotherapy, effector cells must either
be resistant to the deleterious effects of the tumor cells and tumor
microenvironment, or the signaling patterns and immune cell phe-
notypes within the tumor microenvironment must be shifted to
favor an anti-tumor immune response.
Within the tumor microenvironment, CTLs are exposed to
regulatory cytokines and regulatory ligands expressed by the
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tumor cells and neighboring, tolerant immune cells. A num-
ber of molecular modifications to the CTL itself have emerged
and can be improved upon. In successive generations of CARs,
the intracellular signaling domain has been improved to pro-
vide co-stimulatory signaling artificially upon CAR binding of
its target ligand, even when the target cell has downregulated
traditional co-stimulatory molecules. Double-negative recep-
tors, which bind inhibitory ligands on tumor cells or regu-
latory immune cells, are artificial receptors that preferentially
bind the immunosuppressive signal but decouple this binding
from any immunosuppressive effect. Double-negative receptors
that bind TGF-β have been developed and help render CTLs
impervious to its effects (4, 55). Developing double-negative
receptors for PD-L1 and other immunosuppressive members
of the B7 family, or downregulating natively expressed recep-
tors for these and similar molecules on the effector cell, could
improve longevity or cytotoxicity of CTLs targeting HCMV
on GBM.
Tumorigenesis and disease progression requires the subver-
sion, and often recruitment, of the host immune system by the
tumor. The tumor’s ability to control immune checkpoints and
shift endogenous immune cells toward a regulatory phenotype are
central to its ability to persist and progress. Recent efforts tar-
geting the PD1/PD-L1 axis using monoclonal antibodies demon-
strate that anti-tumor effect is possible by shielding endogenous
immune cells from immunosuppressive signaling (56, 57). Per-
haps the greatest promise for immunotherapy lies with inter-
ventions that can reactivate or reprogram an endogenous host
immune response against the tumor. Significant work investigat-
ing the M1/M2 polarization axis and similar pathways involved
in dendritic cell, CD4+ T-cell and CD8+ T cells programing in
the tumor microenvironment is ongoing. Perhaps by manipulat-
ing these tumor-corrupted pathways that immobilize and then
subvert the host immune response, immunotherapy can cure
patients with glioma and other terrible diseases – not necessarily
through effector cells manipulated ex vivo or exogenous cells, but
by reactivating a host army of endogenous immune cells against
the tumor.
At this time, multimodal approaches involving not only
chemotherapy, surgery, or radiation, but also various forms of
immunotherapy, offer the greatest promise for improved clinical
efficacy against GBM and other solid tumors. The presence of
HCMV and the inherent ability of CTLs to target virus-derived
epitopes on glioma cells offer a platform to improve current
immunotherapy for GBM. With an improved ability to create
and sustain an anti-tumor effect within the tumor microenvi-
ronment and potent TAAs such as HCMV, we are optimistic that
immunotherapy for GBM and other tumors will cure patients of
these terrible diseases.
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